Clinical Trial Update: Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China

View source ↗

Summary

A single-center comparative analysis from China assessing how the burden of mucormycosis evolves in patients with hematologic malignancies during the COVID-19 e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Mucormycosis

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Mucormycosis, Hematologic Malignancies | Status: COMPLETED